ImmunityBio Securities Fraud Class Action Targets Cancer Drug ClaimsMay 16, 2026Law and PolicyA securities fraud class action filed May 11 targets ImmunityBio and CEO Patrick Soon-Shiong over alleged false claims that cancer drug Anktiva was a vaccine.
ImmunityBio Faces Securities Fraud Class Action Over Cancer Drug ClaimsMay 4, 2026Law and PolicyA securities fraud class action filed against ImmunityBio targets executive Patrick Soon-Shiong's claim that cancer drug Anktiva is a vaccine, a description the FDA rejected.